| Field | Specification |
|---|---|
| Mfr No | |
| Clonality | |
| Host | |
| Immunogen | E.coli-derived human RAPGEF5 recombinant protein (Position: E164-H574) was used as the immunogen for the RAPGEF5 antibody. |
| Isotype | |
| Product Type | |
| Purity | |
| Reactivity | |
| Storage | |
| Target | |
| UniProt # |
Overview
RAPGEF5 Antibody / Rap guanine nucleotide exchange factor 5 is a anti-RAPGEF5 Rabbit antibody Polyclonal (rabbit origin) supplied in Lyophilized format. Recommended for workflows such as Western blot (WB), ELISA with listed reactivity in Human, Mouse, Rat.
Key elements and design rationale
- Target: RAPGEF5
- Antibody details: Rabbit, Polyclonal (rabbit origin), isotype Rabbit IgG
- Format: Lyophilized
- Applications (as listed): WB, ELISA
Biological background
Functionally, RAPGEF5 antibody identifies a 914-amino-acid cytoplasmic protein containing Ras exchange motif (REM) and CDC25 homology domains responsible for nucleotide exchange activity. RAPGEF5 is regulated by cyclic AMP and interacts with Rap-binding scaffolds to control cell junction assembly and migration. It acts as an important mediator of epithelial integrity and neural development.
The RAPGEF5 gene is located on chromosome 7p15.1 and is expressed in brain, lung, and epithelial tissues. Through Rap GTPase activation, RAPGEF5 coordinates cell-cell adhesion, endothelial barrier function, and axon guidance during development.
Pathologically, altered RAPGEF5 expression has been linked to cancer progression, vascular leakage, and neurological disorders. Dysregulation may lead to impaired Rap signaling, causing aberrant cell polarity and migration. Research using RAPGEF5 antibody supports studies in GTPase signaling, development, and cell adhesion regulation.
RAPGEF5 antibody is validated for western blotting, immunohistochemistry, and immunofluorescence to detect guanine nucleotide exchange factors.
Structurally, Rap guanine nucleotide exchange factor 5 contains a cAMP-binding regulatory domain and catalytic regions that mediate activation of Rap GTPases. This antibody enables detailed analysis of RAPGEF5's contribution to intracellular signaling and polarity control.
Research relevance and current trends
- Connecting protein-level changes to phenotype using orthogonal readouts (genetic perturbation, transcriptomics, imaging).
- Considering isoforms and post-translational regulation when interpreting protein-level changes.
- Comparing results across species and model systems with matched controls.
Common research applications
- Western blotting: compare relative abundance and activation-state changes across conditions.
- ELISA: support antibody-based quantification in assay formats where applicable.
Interpret changes in signal alongside appropriate controls and, when relevant, in parallel with total-protein or pathway readouts.
Notes for experimental interpretation
- Signal can reflect expression level, isoform composition, and post-translational state; interpret results in the context of your model system and stimuli.
- Species differences and sample matrices can influence epitope recognition; prioritize matched controls and orthogonal confirmation when feasible.
Antibody notes: Polyclonal antibodies recognize multiple epitopes, which can broaden the epitope footprint and may increase sensitivity in some contexts.
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
